NCT06808607

Brief Summary

Observational retrospective cohort study to assess clinical outcomes in patients with primary versus secondary antiphospholipid syndrome

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 12, 2025

Completed
24 days until next milestone

First Posted

Study publicly available on registry

February 5, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

February 7, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 6, 2026

Completed
Last Updated

February 5, 2025

Status Verified

January 1, 2025

Enrollment Period

1.1 years

First QC Date

January 12, 2025

Last Update Submit

January 29, 2025

Conditions

Antiphospholipid Syndrome

Keywords

ThrombosisAntiphospholipid syndrome

Outcome Measures

Primary Outcomes (1)

  • to compare percentage of patients with primary versus secondary antiphospholipid syndrome in developing recurrent thrombosis

    12 months

Study Arms (1)

Retrospective to compare clinical outcomes of primary versus secondary antiphospholipi

Observational study to compare clinical outcomes of primary versus secondary antiphospholipid syndrome

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Retrospective cohort

You may qualify if:

  • All patients diagnosed as antiphospholipid syndrome in clinical hematology or rheumatology units in internal medicine department, Assiut university hospital.

You may not qualify if:

  • patients with other risk factor for thrombosis (malignancy, cocs, protein c or protein s deficiency etc

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maha Abdel-Aziz

Asyut, 71515, Egypt

Location

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood sample

MeSH Terms

Conditions

Antiphospholipid SyndromeThrombosis

Condition Hierarchy (Ancestors)

Autoimmune DiseasesImmune System DiseasesEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Central Study Contacts

Maha Abdel-Aziz, Clinical Hematology MD

CONTACT

2001097278659maha.hematology@aun.edu.eg

Yomna Refaat, Clinical Hematology MD

CONTACT

+20 10 60178482yomnarefaat@aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Clinical Hematology, Faculty of medicine, Assiut university

Study Record Dates

First Submitted

January 12, 2025

First Posted

February 5, 2025

Study Start

February 7, 2025

Primary Completion

March 6, 2026

Study Completion

March 6, 2026

Last Updated

February 5, 2025

Record last verified: 2025-01

Locations

EG(1)